PR94693

LISBON, Portugal, Feb 25, 2022, /PRNewswire=KYODO JBN/--

Hovione today announced that the Board of Directors and the shareholders have

approved the appointment of Dr. Jean-Luc Herbeaux as Hovione’s Chief Executive

Officer, effective 1st April 2022.

Guy Villax, who has been Hovione’s CEO for the past 25 years will now serve as

a Member of the Board and shareholder. During his tenure, Hovione grew

tenfold.  The company currently employs 2000 team members, serves the global

market from four production sites in 3 regions, and is recognized as a leader

in its field.  

The Board of Directors expresses its thanks to Guy Villax for his dedication

and outstanding achievements. During his career at Hovione, Guy Villax was also

involved with the EFCG and Rx-360 associations and contributed to legislation

being passed on both sides of the Atlantic to fight fake medicines and to level

the playing field for GMP manufacturing.

“It has been a privilege and honor to lead Hovione over the last decades.

Hovione is a great company because of its people and its clients. It has been

an amazing entrepreneurial and human journey with so many projects and

unforgettable success stories. I have seen this company, founded by my parents,

growing, evolving and constantly re-inventing itself”, said Guy Villax. “Dr.

Herbeaux joined Hovione nearly two years ago as COO and from day 1 brought

change and contributed to financial and business successes.  We have worked

together both on the strategy which will take Hovione to the next level and on

making this transition smooth. I am certain that both the company and our

Team-Members will continue to thrive under his leadership”, added Guy Villax.  

“I am honored to be entrusted with the role of Hovione’s CEO and I am deeply

motivated to lead this team of talented professionals. Building on Guy Villax´s

legacy of innovation and customer intimacy, we will continue to work to drive

long-term growth for both ourselves and our customers maintaining the Hovione

values. Hovione puts customers and patients at the center of everything it does

and this focus will not change. Our customers can expect us to continue to

deliver on what we promise and to offer innovative approaches to their project

needs.”, said Jean-Luc Herbeaux.

Before joining Hovione in May 2020, Dr. Herbeaux held multiple high-level

leadership positions at Evonik, where he last headed the Health Care Business

Line Dr. Herbeaux holds both a Master of Science and a Ph.D. in Mechanical

Engineering with a research focus on Rheology from the University of Houston.

About Hovione

Hovione [https://www.hovione.com/] is an international company with over 60

years of experience as a Contract Development and Manufacturing Organization

(CDMO) and is currently a fully integrated supplier offering services for drug

substance, drug product intermediate and drug product. With four FDA inspected

sites [https://www.hovione.com/hovione-worldwide] in the USA, China, Ireland,

and Portugal and development laboratories in Lisbon, Portugal and New Jersey,

USA, the company provides branded pharmaceutical customers services for the

development and compliant manufacture

[https://www.hovione.com/products-and-services/contract-manufacturing-services/p

article-engineering] of innovative drugs including highly potent compounds and

customized product solutions across the entire drug life cycle. In the

inhalation area, Hovione offers a complete range of and services, from API,

formulation development and devices. Hovione was the first Chemical/

Pharmaceutical Company to became a Certified B Corp

[https://www.hovione.com/about-hovione/sustainability/b-corporation], is a

member of Rx-360, EFCG and participates actively in the industry standard

setting process.  Please visit www.hovione.com

Contact

Isabel Pina | Director External Communications

ipina@hovione.com |Tel.: 0035121 982 9362

Photo - https://mma.prnewswire.com/media/1754437/Hovione.jpg

Logo - https://mma.prnewswire.com/media/1686008/Logo_Hovione_Logo.jpg

Source: Hovione